Allon Therapeutics Inc. (TSX:NPC)

Chromos Molecular Systems Inc. (TSX:CHR)

Medical Ventures Corp. (TSX-V:MEV)

MSI Methylation Sciences, Inc.

Neuromed Pharmaceuticals Ltd.

Protox Therapeutics Inc. (TSX:PRX)

Allon Therapeutics Inc. (TSX:NPC) is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer’s disease, mild cognitive impairment, traumatic brain injury, stroke, multiple sclerosis and neuropathy. Allon’s drug discovery platform has resulted in the development of a unique class of peptide compounds that has demonstrated broad efficacy in numerous pre-clinical models of neurodegenerative diseases.

Chromos Molecular Systems Inc. (TSX:CHR) is a biotechnology company committed to the development and commercialization of innovative therapeutic products based on its two proprietary platforms: the Artificial Chromosome Expression (ACE) System and Rapid Expansion Method (REM). Chromos is using these unique approaches to develop immune – and gene-based cell therapies, and to engineer cell lines for biopharmaceutical production.

Medical Ventures Corp. (TSX-V:MEV) develops, manufactures and markets medical devices for the quickly growing vascular and surgical marketplace. MEV products help doctors treat a wide range of health concerns, including vascular disease and obesity.

MSI Methylation Sciences, Inc. Methylation Sciences is a life science company, focused on reformulating and developing a widely used nutraceutical, with proven safety and efficacy in humans, as a new pharmaceutical for the treatment of depression. MSI is led by an experienced management team including Barry Guld and Nancy Harrison.

Neuromed Pharmaceuticals Ltd. is a privately held biopharmaceutical company in business to develop safer and more effective pain drugs. Neuromed combines it pharmaceutical expertise in research, development and commercialization to improve existing pain treatments as well as develop new pain medicines.

Protox Therapeutics Inc. (TSX:PRX) is at the forefront of developing novel treatments in the emerging field of targeted toxin therapeutics for the treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin(TM), in the development of therapeutic products for its clinical programs.